Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (181-190 of 635) with videos related to

Pageof 64
Sort By:
Journal of Affective Disorders|August 28, 2022
General Anxiety Disorder-7 Questionnaire as a marker of low socioeconomic status and inequityJulio C Nunes, Megan K Carroll, Kenneth W Mahaffey, et al.
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trialMichael P Hudson, Paul W Armstrong, William W O'Neil, et al.
European Heart Journal|December 3, 2009
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarctionMichael C Tjandrawidjaja, Yuling Fu, Cynthia M Westerhout, et al.
Circulation|March 30, 2026
Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID TrialsSreekanth Vemulapalli, Karla Pena Guerra, Daniel Wojdyla, et al.
The Lancet. Rheumatology|January 17, 2024
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS ProgramJingWei Li, Sunil V Badve, Zien Zhou, et al.
Journal of the American Heart Association|January 30, 2020
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-AnalysisClare Arnott, Qiang Li, Amy Kang, et al.
American Heart Journal|March 30, 2013
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryBenjamin A Steinberg, DaJuanicia N Holmes, Michael D Ezekowitz, et al.
Circulation. Cardiovascular Quality and Outcomes|May 13, 2017
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Ryan Orgel, Daniel Wojdyla, David Huberman, et al.
Circulation. Cardiovascular Imaging|May 14, 2026
Impact of the 2025 ASE Guidelines on the Classification of LV Diastolic Dysfunction in the Community: A Project Baseline Health StudyNancy Herrera-Leaño, Bettia Celestin, Everton Santana, et al.
American Heart Journal|July 12, 2011
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction"John K French, Paul W Armstrong, Eric Cohen, et al.
Pageof 64

Showing results (181-190 of 635) with videos related to

Sort By:
Pageof 64
Journal of Affective Disorders|August 28, 2022
General Anxiety Disorder-7 Questionnaire as a marker of low socioeconomic status and inequityJulio C Nunes, Megan K Carroll, Kenneth W Mahaffey, et al.
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trialMichael P Hudson, Paul W Armstrong, William W O'Neil, et al.
European Heart Journal|December 3, 2009
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarctionMichael C Tjandrawidjaja, Yuling Fu, Cynthia M Westerhout, et al.
Circulation|March 30, 2026
Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID TrialsSreekanth Vemulapalli, Karla Pena Guerra, Daniel Wojdyla, et al.
The Lancet. Rheumatology|January 17, 2024
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS ProgramJingWei Li, Sunil V Badve, Zien Zhou, et al.
Journal of the American Heart Association|January 30, 2020
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-AnalysisClare Arnott, Qiang Li, Amy Kang, et al.
American Heart Journal|March 30, 2013
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryBenjamin A Steinberg, DaJuanicia N Holmes, Michael D Ezekowitz, et al.
Circulation. Cardiovascular Quality and Outcomes|May 13, 2017
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Ryan Orgel, Daniel Wojdyla, David Huberman, et al.
Circulation. Cardiovascular Imaging|May 14, 2026
Impact of the 2025 ASE Guidelines on the Classification of LV Diastolic Dysfunction in the Community: A Project Baseline Health StudyNancy Herrera-Leaño, Bettia Celestin, Everton Santana, et al.
American Heart Journal|July 12, 2011
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction"John K French, Paul W Armstrong, Eric Cohen, et al.
Pageof 64